Trial Profile
A phase I, multicenter, randomized, parallel, double-blinded dose ranging, placebo-controlled study to compare antiviral effect, safety, tolerability and pharmacokinetics of four oral dosage regimens of GW695634G monotherapy versus placebo over 10 days in ART-naive HIV-1 infected adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs GW 695634 (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors GSK
- 11 Oct 2005 New trial record.